Rxo (RXO) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to -$0.27.
- Rxo's EPS (Weighted Average and Diluted) fell 125000.0% to -$0.27 in Q4 2025 from the same period last year, while for Dec 2025 it was -$0.58, marking a year-over-year increase of 7128.71%. This contributed to the annual value of -$0.59 for FY2025, which is 7281.11% up from last year.
- Rxo's EPS (Weighted Average and Diluted) amounted to -$0.27 in Q4 2025, which was down 125000.0% from -$0.08 recorded in Q3 2025.
- Rxo's 5-year EPS (Weighted Average and Diluted) high stood at $0.38 for Q2 2022, and its period low was -$1.81 during Q3 2024.
- In the last 5 years, Rxo's EPS (Weighted Average and Diluted) had a median value of -$0.02 in 2024 and averaged -$0.07.
- Per our database at Business Quant, Rxo's EPS (Weighted Average and Diluted) soared by 12500.0% in 2023 and then plummeted by 1800000.0% in 2024.
- Rxo's EPS (Weighted Average and Diluted) (Quarter) stood at $0.36 in 2021, then tumbled by 111.11% to -$0.04 in 2022, then surged by 125.0% to $0.01 in 2023, then tumbled by 300.0% to -$0.02 in 2024, then tumbled by 1250.0% to -$0.27 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.27 in Q4 2025, compared to -$0.08 in Q3 2025 and -$0.05 in Q2 2025.